FI3356827T3 - GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi - Google Patents
GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi Download PDFInfo
- Publication number
- FI3356827T3 FI3356827T3 FIEP16779036.9T FI16779036T FI3356827T3 FI 3356827 T3 FI3356827 T3 FI 3356827T3 FI 16779036 T FI16779036 T FI 16779036T FI 3356827 T3 FI3356827 T3 FI 3356827T3
- Authority
- FI
- Finland
- Prior art keywords
- hgdf
- binding
- cancer
- antigen
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1517527.6A GB201517527D0 (en) | 2015-10-02 | 2015-10-02 | GDF-15 as a diagnosis marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| GBGB1607800.8A GB201607800D0 (en) | 2016-04-29 | 2016-04-29 | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| PCT/EP2016/073519 WO2017055612A1 (en) | 2015-10-02 | 2016-09-30 | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3356827T3 true FI3356827T3 (fi) | 2024-01-03 |
Family
ID=57123979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16779036.9T FI3356827T3 (fi) | 2015-10-02 | 2016-09-30 | GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11262360B2 (https=) |
| EP (2) | EP4321866A3 (https=) |
| JP (1) | JP6858181B2 (https=) |
| KR (1) | KR102621034B1 (https=) |
| AU (1) | AU2016333538B2 (https=) |
| CA (1) | CA3000290C (https=) |
| DK (1) | DK3356827T3 (https=) |
| ES (1) | ES2968226T3 (https=) |
| FI (1) | FI3356827T3 (https=) |
| WO (1) | WO2017055612A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59045B1 (sr) * | 2012-09-26 | 2019-08-30 | Univ Wuerzburg J Maximilians | Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15) |
| US10509045B2 (en) | 2015-05-29 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Methods for diagnosing Huntington's disease |
| FI3356827T3 (fi) | 2015-10-02 | 2024-01-03 | Univ Wuerzburg J Maximilians | GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi |
| US10940161B2 (en) | 2016-04-04 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| WO2018195110A1 (en) | 2017-04-17 | 2018-10-25 | University Of Florida Research Foundation, Incorporated | Regolation of ran translation by pkr and eif2a-p pathways |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| EP3688020A4 (en) | 2017-09-25 | 2021-07-14 | University of Florida Research Foundation, Incorporated | IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| KR102164432B1 (ko) | 2019-09-18 | 2020-10-13 | 한국과학기술원 | Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법 |
| WO2021055880A1 (en) | 2019-09-20 | 2021-03-25 | University Of Florida Researchfoundation, Incorporated | Detection of antibodies against ran proteins from serum and tissue lysates |
| KR102238912B1 (ko) | 2020-05-27 | 2021-04-12 | 한국과학기술원 | Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법 |
| CN112162097B (zh) * | 2020-07-24 | 2022-04-01 | 广州医科大学 | Gdf1作为评估pd-1单抗治疗效果的生物标志物 |
| KR20230107309A (ko) | 2020-11-10 | 2023-07-14 | 카탈임 게엠베하 | 항-gdf15 항체 및 암 치료용 투여 용법 |
| CN112698042A (zh) * | 2020-12-17 | 2021-04-23 | 北京赛诺浦生物技术有限公司 | 检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用 |
| CN113252905A (zh) * | 2021-05-12 | 2021-08-13 | 北京赛诺浦生物技术有限公司 | 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用 |
| CN113702647B (zh) * | 2021-08-31 | 2024-03-15 | 普十生物科技(北京)有限公司 | 人生长分化因子15即时检测试剂盒、其制备方法及其应用 |
| KR20230046264A (ko) | 2021-09-29 | 2023-04-05 | (주)펜타메딕스 | Line-1의 dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법 |
| CN115831306A (zh) * | 2023-02-23 | 2023-03-21 | 北京康博众联电子科技有限公司 | 一种数据分析装置、方法及计算机存储介质 |
| CN116462757A (zh) * | 2023-03-24 | 2023-07-21 | 科兴生物制药股份有限公司 | Gdf15的单域抗体及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| JP2002543841A (ja) | 1999-05-17 | 2002-12-24 | バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー | ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性 |
| AU2001288770A1 (en) | 2000-09-08 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| SI2311873T1 (sl) | 2004-01-07 | 2018-12-31 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specifična monoklonska protitelesa in njihova uporaba |
| EP2441466B1 (en) | 2004-04-13 | 2014-07-23 | St Vincent's Hospital Sydney Limited | MIC-1 inhibiting agent |
| US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| CN101896192A (zh) | 2007-10-09 | 2010-11-24 | 圣文森特医院悉尼有限公司 | 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法 |
| WO2009150255A2 (en) | 2008-06-13 | 2009-12-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Markers for predicting response and survival in anti-egfr treated patients |
| NZ591484A (en) | 2008-09-29 | 2012-09-28 | Roche Glycart Ag | Antibodies against human il 17 and uses thereof |
| EP2209003A1 (en) * | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| US7736861B1 (en) | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
| TWI452136B (zh) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| EP2714738B1 (en) * | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| EP2565262A1 (en) | 2011-08-31 | 2013-03-06 | VTU Holding GmbH | Protein expression |
| EP3683228A3 (en) | 2012-01-26 | 2020-07-29 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| RS59045B1 (sr) | 2012-09-26 | 2019-08-30 | Univ Wuerzburg J Maximilians | Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15) |
| ES2791183T3 (es) | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| US11021752B2 (en) * | 2013-03-15 | 2021-06-01 | Myriad Genetics, Inc. | Genes and gene signatures for diagnosis and treatment of melanoma |
| JP2015078138A (ja) | 2013-10-15 | 2015-04-23 | 株式会社ニックス | 小動物防除性樹脂組成物 |
| AU2015206603B9 (en) * | 2014-01-14 | 2019-07-18 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms |
| EP2899544B1 (en) * | 2014-01-28 | 2018-12-26 | Roche Diagnostics GmbH | Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy |
| KR102410090B1 (ko) | 2014-02-21 | 2022-06-16 | 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 | 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 |
| RS59700B1 (sr) | 2014-03-26 | 2020-01-31 | Univ Wuerzburg J Maximilians | Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera |
| PL3197493T3 (pl) | 2014-09-25 | 2021-08-23 | Aveo Pharmaceuticals Inc. | Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego |
| FI3356827T3 (fi) | 2015-10-02 | 2024-01-03 | Univ Wuerzburg J Maximilians | GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi |
| CN108463246B (zh) | 2015-10-02 | 2025-02-28 | 尤利乌斯·马克西米利安维尔茨堡大学 | 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗 |
| GB201517528D0 (en) | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
| CN112912395B (zh) | 2018-08-20 | 2024-08-23 | 辉瑞公司 | 抗gdf15抗体、组合物和使用方法 |
-
2016
- 2016-09-30 FI FIEP16779036.9T patent/FI3356827T3/fi active
- 2016-09-30 DK DK16779036.9T patent/DK3356827T3/da active
- 2016-09-30 JP JP2018516740A patent/JP6858181B2/ja active Active
- 2016-09-30 EP EP23206060.8A patent/EP4321866A3/en not_active Withdrawn
- 2016-09-30 WO PCT/EP2016/073519 patent/WO2017055612A1/en not_active Ceased
- 2016-09-30 CA CA3000290A patent/CA3000290C/en active Active
- 2016-09-30 AU AU2016333538A patent/AU2016333538B2/en active Active
- 2016-09-30 KR KR1020187012419A patent/KR102621034B1/ko active Active
- 2016-09-30 EP EP16779036.9A patent/EP3356827B1/en active Active
- 2016-09-30 ES ES16779036T patent/ES2968226T3/es active Active
- 2016-09-30 US US15/765,174 patent/US11262360B2/en active Active
-
2022
- 2022-01-20 US US17/580,245 patent/US12473354B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2968226T3 (es) | 2024-05-08 |
| EP3356827B1 (en) | 2023-12-06 |
| CA3000290A1 (en) | 2017-04-06 |
| EP3356827A1 (en) | 2018-08-08 |
| WO2017055612A1 (en) | 2017-04-06 |
| US20180292412A1 (en) | 2018-10-11 |
| KR102621034B1 (ko) | 2024-01-03 |
| JP2018535404A (ja) | 2018-11-29 |
| EP4321866A2 (en) | 2024-02-14 |
| AU2016333538B2 (en) | 2022-03-31 |
| AU2016333538A1 (en) | 2018-04-26 |
| JP6858181B2 (ja) | 2021-04-14 |
| KR20180054867A (ko) | 2018-05-24 |
| US11262360B2 (en) | 2022-03-01 |
| DK3356827T3 (da) | 2024-01-08 |
| US12473354B2 (en) | 2025-11-18 |
| US20220242942A1 (en) | 2022-08-04 |
| CA3000290C (en) | 2023-02-21 |
| EP4321866A3 (en) | 2024-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3356827T3 (fi) | GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi | |
| JP2018535404A5 (https=) | ||
| JP2015533788A5 (https=) | ||
| RU2015103228A (ru) | Антитела против тау | |
| JP2017518366A5 (https=) | ||
| JP2012515226A5 (https=) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2012019790A5 (https=) | ||
| JP2017524725A5 (https=) | ||
| JP2018520668A5 (https=) | ||
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| RU2016109642A (ru) | Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1 | |
| JP2020530272A5 (https=) | ||
| JP2014524744A5 (https=) | ||
| WO2007109376A3 (en) | Anti-tumor cell antigen antibody therapeutics | |
| CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
| JP2016533395A5 (https=) | ||
| JP2015502547A5 (https=) | ||
| MX357292B (es) | Método para detectar cáncer. | |
| RU2016116773A (ru) | Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы | |
| FI3356826T3 (fi) | Gdf-15 melanooman diagnostisena markkerina | |
| JP2013536419A5 (https=) | ||
| RU2016129166A (ru) | Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии | |
| JP2015529633A5 (https=) | ||
| RU2671578C2 (ru) | Способ прогнозирования риска возникновения рака или диагностирования рака у женщины |